SAN DIEGO, April  06, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC). The investigation focuses on ORIC&#39;s executive

ORIC

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

ORIC Pharmaceuticals Faces Investor Investigation Following Significant Stock Drop

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, April  06, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC). The investigation focuses on ORIC&amp;#39;s executive</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel is probing ORIC Pharmaceuticals for potential securities law violations after the stock plummeted 26% post-clinical data release. Investors may pursue recovery of losses based on the company&#039;s disclosures about its lead clinical program.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel is investigating potential investor claims against ORIC Pharmaceuticals.</li><li>The investigation concerns executive actions and federal law compliance.</li><li>ORIC reported a 26% stock price drop following recent clinical trial data.</li><li>PSA50 response rate was reported at 47%, indicating mixed clinical efficacy.</li><li>Investor losses may be recoverable under federal securities laws.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ORIC Pharmaceuticals (ORIC)</strong>: Leading drug trials led to significant stock drops and investor investigations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments, as it involves legal investigations that may impact ORIC&#039;s financial and operational stability.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Potential federal securities claims may further depress ORIC stock prices.</li><li>The significant 26% drop could signal bearish market sentiment for ORIC.</li><li>Continued investor investigations might hinder ORIC&#039;s market recovery.</li><li>Clinical trial results could affect investor confidence and stock volatility.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Johnson Fistel is conducting the investigation as of April 6, 2026.</li><li>ORIC stock fell approximately 26% on April 1, 2026.</li><li>PSA50 response rate in the trial was reported at about 47%.</li><li>Confirmed responses among patients were around 33%, from a sample of 15.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting ORIC based on recent volatility and potential legal troubles in the near term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, April  06, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ORIC">ORIC</a>). The investigation focuses on ORIC's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased ORIC securities?</strong><br></br>If you purchased ORIC securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=kOcM1oElzF-T6D35gKwtzQjaEXRknPp73m4nzQunC_QsUSi-kpHQ8Ctg1pah7rMOY7Npjbg-h4NU4-kr6MY7y6Nz2AB6SU8qfELNyyEWvCNtGF8YvSLkRpNCcf6wRNyNIzoHJ6XzvPE-xIpevM6SIfv-fFyOnDhqiSTybHvj93UXJ8PMgv-YrcpIt9nQ11Vj" rel="nofollow" target="_blank">Click here to join the investigation</a>.<br></br>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.<br></br>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On March 31, 2026, ORIC reported additional clinical data and provided updates regarding its lead clinical program. Among other things, the Company disclosed that the selected dose was based on tolerability considerations and that comparable efficacy was observed across doses. The Company further reported a PSA50 response rate of approximately 47% (7/15 patients) and confirmed responses of approximately 33% (5/15 patients) in the relevant patient population.</p>  <p>Following these disclosures, the price of ORIC stock declined approximately 26% on April 1, 2026, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether ORIC complied with the federal securities laws. If you suffered losses from your investment in ORIC stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=UQeFdB1zVXUQiFSa0Hp4zJ1cj1tTcg7jtoZd4_Hn9xyB21jpsAii8Kmqnpvlg76rHFVjRWtxflkURwc9SzN5WHf2Zd_f2F9wGdOnFNkDMn8=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NDUxMiM3NTE4OTk2IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NTE2NzU0ZGQtNzA4Ny00OGFmLWI0MGItZWVhOGI3MTNhNGJjLTExOTMzNTgtMjAyNi0wNC0wNi1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Johnson Fistel is probing ORIC Pharmaceuticals for potential securities law violations after the stock plummeted 26% post-clinical data release. Investors may pursue recovery of losses based on the company's disclosures about its lead clinical program.

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News